# Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease

> **NCT07495033** · PHASE3 · NOT_YET_RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 260 (estimated)

## Conditions studied

- CTD-ILD

## Interventions

- **DRUG:** Telitacicept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07495033
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2029-05-31
- **Final completion:** 2030-05-31
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07495033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07495033, "Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07495033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*